Abstract | INTRODUCTION:
Acyltransferase (AT) catalyzes the transfer of an acyl moiety from acyl-coenzyme A ( acyl-CoA) to an acceptor. ATs play important roles in the maintenance of homeostasis in the human body and have been linked to various diseases; therefore, several ATs have been proposed as potential targets for the treatment or prevention of such diseases. The AT family includes acyl-CoA: cholesterol AT (ACAT), diacylglycerol AT (DGAT), and monoacylglycerol AT (MGAT) for the metabolism of lipids. Furthermore, recent molecular biological studies revealed the existence of their isozymes with distinct functions in the body. AREAS COVERED: This review summarized patent filings published between 2010 and the present date that claimed isozyme-selective inhibitors of ACAT, DGAT and MGAT, which are involved in neutral lipid metabolism. EXPERT OPINION:
|
Authors | Taichi Ohshiro, Hiroshi Tomoda |
Journal | Expert opinion on therapeutic patents
(Expert Opin Ther Pat)
Vol. 25
Issue 2
Pg. 145-58
(Feb 2015)
ISSN: 1744-7674 [Electronic] England |
PMID | 25470667
(Publication Type: Journal Article, Review)
|
Chemical References |
- Isoenzymes
- Acyltransferases
|
Topics |
- Acyltransferases
(antagonists & inhibitors)
- Animals
- Atherosclerosis
(drug therapy, enzymology)
- Drug Design
- Humans
- Hyperlipoproteinemia Type II
(drug therapy, enzymology)
- Isoenzymes
- Lipid Metabolism
(drug effects)
- Molecular Targeted Therapy
- Non-alcoholic Fatty Liver Disease
(drug therapy, enzymology)
- Patents as Topic
|